| ²é¿´: 1747 | »Ø¸´: 5 | |||
ÐÂÊÖÒÑÉÏ·ľ³æ (Ö°Òµ×÷¼Ò)
|
[½»Á÷]
άÉúËØCÒýµ¼µÄÌØ¶¨Í»±ä°©Ï¸°ûÑõ»¯ËÀÍö ÒÑÓÐ3È˲ÎÓë
|
|
11ÔÂ5ÈÕ£¬¡¶Science¡·ÔÓÖ¾·¢±íÒ»ÏîÑо¿£¬À´×ÔÍþ¶û¿µÄζûҽѧԺ£¬ÀäȪ¸ÛʵÑéÊÒ£¬Ëþ·ò´ÄҽѧÖÐÐÄ£¬¹þ·ðҽѧԺºÍÔ¼º²¡¤»ôÆÕ½ð˹kimmel°©Ö¢ÖÐÐĵÄÑо¿Õß·¢ÏÖ£¬¸ß¼ÁÁ¿µÄάÉúËØC -´óÔ¼Ï൱ÓÚ300¸öéÙ×ÓµÄÁ¿£¬ÔÚϸ°ûÅàÑø»·¾³ÀïºÍСÊóÀïËð»µÁËKRASºÍBRAFÍ»±äÔì³ÉµÄ½áÖ±³¦°©µÄÉú³¤¡£ÕâÏî·¢ÏÖ¿ÉÄܻᵼÖÂеÄÖÎÁÆ·½·¨µÄ·¢Õ¹£¬²¢Ìṩ¹Ø¼üµÄ¼û½â£¬Ë½«×îÊÜÒæÓÚËûÃÇ¡£¸ù¾ÝÒ»ÏîеÄÑо¿´ÓÍþ¶û¿µÄζûҽѧµ÷²é£º¸ßˮƽµÄάÉúËØCÄÜÔÚϸ°ûÅàÑø»·¾³ÀïºÍСÊóÉÏɱËÀijЩÀàÐ͵Ľ᳦ֱ³¦°©,¡£Ñо¿½á¹û±íÃ÷¿ÆÑ§¼Ò¿ÉÒÔÀûÓÃÒ»ÌìάÉúËØC¿ª·¢ÓÐÕë¶ÔÐÔµÄÖÎÁÆ¡£Íþ¶û¿µÄζûҽѧԺµÄLewis CantleyÑо¿×鲩ʿºóJihye YunΪÂÛÎĵÚÒ»×÷Õߣ¬Lewis CantleyÑо¿Ô±ÎªÂÛÎÄͨѶ×÷Õß¡£ ½áÖ±³¦°©ÊÇÃÀ¹úµÚÈý´ó³£¼ûµÄ¼²²¡£¬Ã¿ÄêÔ¼ÓÐ93090в¡Àý¡£´óÔ¼Ò»°ëµÄ°¸ÀýÊÇKRASºÍBRAF»ùÒòÍ»±äÔì³ÉµÄ£¬ÕâÖÖÍ»±äÐÎʽÔì³ÉµÄ¼²²¡(¶ÔÈËÌå)¸ü¾ßÓÐÇÖÂÔÐÔÒÔ¼°µ±Ç°µÄÖÎÁÆ»ò»¯ÁƶԼ²²¡Ã»ÓÐЧ¹û¡£ ¡°ÎÒÃǵķ¢ÏÖΪ̽Ë÷άÉúËØCÖÎÁÆKRASºÍBRAFÍ»±äÐγɵĽáÖ±³¦°©ÖÎÁÆÌṩÁË»úеÔÀí£¬¡±×ÊÉî×÷ÕßLewis Cantley²©Ê¿Ëµ£¬Í¬Ê±ÊÇËûÒ²ÊÇÉ£µÂÀºÍ°®µÂ»ª¡¤Ã·¶û°©Ö¢ÖÐÐĵĸºÔðÈ˺ÍÂê¸ñÀöÌØ¡¤ºÕ¶ûÂü¡¤¿Æ¶ûÍþ¶û¿µÄζûҽѧÖ×ÁöѧÑо¿µÄ½ÌÊÚ¡£ ´«Í³¹ÛµãÈÏΪ£¬Î¬ÉúËØDÄÜÌá¸ßÉíÌ彡¿µ£¬²¿·ÖÔÒòÊÇÒòΪËü¿ÉÒÔ×÷ΪһÖÖ¿¹Ñõ»¯¼Á£¬·ÀÖ¹»òÑÓ»ºÄ³Ð©ÀàÐ͵Äϸ°ûËðÉË¡£È»¶ø£¬Cantley²©Ê¿ºÍËûµÄͬÊÂÃÇ·¢ÏÖ£¬Ïà·´µÄÊÇÕæÊµµÄ¹ØÓÚ´ó¼ÁÁ¿Î¬ÉúËØCµÄÖÎÁƵÄÓ°Ï죬¶ÔµÄKRASºÍBRAFÍ»±äÐγɵĽáÖ±³¦°©£¬¾Íǡǡ·¢ÉúÔÚ¶ÔÕâЩ°©Ï¸°ûµÄÓÕµ¼Ñõ»¯ÉÏ¡£ ÔÚ¸»Ñõ»·¾³ÈçÈ˵͝Âö£¬Î¬ÉúËØCµÄº¬Á¿£¬Ò²½Ð¿¹»µÑªËᣬΪÑõ»¯²¢×ª»¯ÎªÒ»ÖÖÐµĻ¯ºÏÎï³ÆÎªÍÑÇ⿹»µÑªËá(DHA)¡£¿ÆÑ§¼ÒÃÇÒѾ֪µÀÁËÒ»Õóʱ¼äÓÐÌØ¶¨µÄĤµ°°×£¬³ÆÎªÆÏÌÑÌÇתÔ˵°°×GLUT1£¬Ê¹ÆÏÌÑÌǺÍDHA½øÈëϸ°û£¬Õâ¸öϸ°û»î¶¯²»Ìṩ¿¹»µÑªËá¡£µ«ÈËÃDz»Çå³þµÄDHA½øÈëϸ°ûµÄ×÷ÓᣠÔÚÕâÏîÑо¿ÖУ¬Ñо¿ÈËÔ±·¢ÏÖ£¬DHAµÄ×÷ÓþÍÏñÒ»¸öľÂí¡£Ò»µ©½øÈëϸ°ûÄÚ£¬°©Ï¸°ûÀïÃæµÄÌìÈ»¿¹Ñõ»¯¼ÁÊÔͼ½«DHAת±ä»Ø¿¹»µÑªËá;ÔÚÕâ¸ö¹ý³ÌÖУ¬ÕâЩ¿¹Ñõ»¯¼Á¿Ý½ßͬʱϸ°ûÒòÑõ»¯Ó¦¼¤¶øËÀÍö¡£ ¡°ËäÈ»Ðí¶àÕý³£Ï¸°ûÒ²±í´ïGLUT1£¬KRASÍ»±äºÍBRAFÍ»±äµÄ°©Ï¸°ûͨ³£Óиü¸ßˮƽµÄGLUT1±í´ï£¬ÒòΪËûÃÇÐèÒªÒ»¸ö¸ßËÙÂÊµÄÆÏÌÑÌÇÉãȡΪÁËÉú´æºÍ³É³¤¡±Cantley²©Ê¿Ëµ¡£¡±Í¬Ê±£¬KRASºÍBRAFÍ»±äµÄϸ°û±ÈÕý³£Ï¸°û²úÉú¸ü¶àµÄ»îÐÔÑõÎïÖÖ£¬Òò´ËΪÁËÉú´æÐèÒª¸ü¶àµÄ¿¹Ñõ»¯¼Á¡£ÕâÐ©ÌØÕ÷µÄ½áºÏʹµÃÕâЩ°©Ï¸°û±ÈÕý³£Ï¸°û»òÆäËûÀàÐ͵ݩϸ°ûDHA¸üÈÝÒ×Êܵ½É˺¦¡£¡± ËäÈ»²©Ê¿Cantley¾¯¸æËµ£¬ÕâЩ½á¹ûÐèÒªÔÚÈËÌåÁÙ´²ÊÔÑé½øÐÐÆÀ¼Û£¬µ«ÁÙ´²Ç°Ñо¿½á¹û¿ÉÄÜÌṩһ¸öеÄÓÐǰ;µÄKRAS»òBRAF»ùÒòÍ»±äÐγɵݩ֢ÖÎÁƲßÂÔ£¬Ò²Ðí×÷Ϊ×ÛºÏÖÎÁƵÄÒ»²¿·Ö¡£Ñо¿ÈËԱ˵£¬ËûÃǵÄÑо¿¿ÉÄܻᵼÖÂеÄÉúÎï±êÖ¾ÎïµÄ·¢Õ¹£¬¿ÉÒÔ°ïÖúÒ½ÉúÈ·¶¨Ë½«×îÊÜÒæÓÚÕâÖÖÖÎÁÆ·½·¨¡£ÕâЩ¼û½â£¬Ò²¿ÉÄÜÓÐÆäËûÄÑÒÔÖÎÁƵĸßˮƽ±í´ïGLUT1תÔËÌåµÄ°©Ö¢Ôì³ÉÓ°Ï죬ÈçÉöϸ°û°©£¬°òë×°©ºÍÒÈÏÙ°©¡£ άÉúËØCÔÚ³ýÁËÆä·´»ò´ÙÑõ»¯×÷ÓöÔϸ°û¹¦ÄÜµÄ¶à·½ÃæµÄÓ°Ï죬ËùÒÔÕâÊǶԴó¼ÁÁ¿Î¬ÉúËØC¶ÔÕý³£ÃâÒßϸ°ûµÄÓ°ÏìµÄÒ»ÏîÖØÒªÑо¿£¬Cantley²©Ê¿µÄʵÑéÊҵIJ©Ê¿ºóÑо¿Ô±¡¢ÂÛÎĵÚÒ»×÷ÕßJihye Yun²©Ê¿Ëµ¡£ ¡°¿Ï¶¨ÊÇÐèÒª½øÒ»²½µÄÑо¿À©´óÎÒÃǶÔÕâЩ¹ý³ÌµÄÀí½â¡£µ«ÏÖÔÚÎÒÃǼÈÈ»ÒѾ֪µÀµÄÕâ¸ö»úÖÆ£¬ÎÒÃÇ¿ÉÒÔÃ÷ÖǵØÀûÓÃ֪ʶÀ´»ñµÃÏëÒªµÄЧ¹û¡°Ëý˵¡£ ¡°Õâ²»ÊÇÒ»¸öÖÎÁÆ£¬Ã»ÓÐÁ˽âÄãµÄÖ×ÁöÄÚ²¿·¢ÉúÁËʲô¾ÍÊÇÔÚäĿµØÂþ²½¡±²©Ê¿Cantley˵¡£ ¼ÁÁ¿½¨Ò黹ÐèҪȷ¶¨¡£ÖÎÁÆÐ§¹û¿ÉÄÜÐèÒª¾²Âö×¢É䣬ÒòΪ¿Ú·þ¼ÁÁ¿ÔÚ³¦µÀÖв»ÄÜÓÐЧµØÎüÊÕ£¬ÐèÒªÒÔ´ïµ½¸ßѪҩŨ¶ÈµÄάÉúËØDÒý·¢°©Ï¸°ûµÄ¶¾ÐÔ¡£×î½üµÄÒ»ÆÚÈËÀàÁÙ´²ÊÔÑé²âÊÔ±íÃ÷£¬¾²ÂöÊäÒºÔÚ¼ÁÁ¿µÄάÉúËØC,ת»¯ÎªÀàËÆË®Æ½µÄѪÇå×÷Ϊ¿²ÌØÀÏÊóÊÔÑéÓкܺõݲȫÅäÖÃÎļþ¡£ ÎÒÃÇÏ£ÍûÎÒÃǵÄÑо¿ÄÜÈÿÆÑ§½çÖØÐÂÉóÊÓÕâ¸ö°²È«¡¢Á®¼ÛµÄÌìÈ»·Ö×Ӻʹ̼¤»ù´¡ºÍÁÙ´²Ñо¿¹ØÓÚάÉúËØC×÷Ϊ°©Ö¢ÖÎÁƵķ½·¨¡±Jihye Yun²©Ê¿Ëµ¡£ ÔÎÄÁ´½Ó£º Vitamin C selectively kills KRAS and BRAF mutant colorectal cancer cells by targeting GAPDH ÔÎÄÕªÒª£º More than half of human colorectal cancers (CRCs) carry either KRAS or BRAF mutations, and are often refractory to approved targeted therapies. We report that cultured CRC cells harboring KRAS or BRAFmutations are selectively killed when exposed to high levels of vitamin C. This effect is due to increased uptake of the oxidized form of vitamin C, dehydroascorbate (DHA), via the GLUT1 glucose transporter. Increased DHA uptake causes oxidative stress as intracellular DHA is reduced to vitamin C, depleting glutathione. Thus, ROS accumulates and inactivates glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Inhibiting GAPDH in highly glycolytic KRAS or BRAF mutant cells leads to an energetic crisis and cell death not seen in KRAS and BRAF wild-type cells. High-dose vitamin C impaired tumor growth in Apc/KrasG12Dmutant mice. These results provide a mechanistic rationale for exploring the therapeutic use of vitamin C forCRCs with KRAS or BRAF mutations. |
» ±¾ÌûÒÑ»ñµÃµÄºì»¨£¨×îÐÂ10¶ä£©
» ²ÂÄãϲ»¶
ʱÆÀ£ºÉú²ú¼ÙÒ©£¬Ã»ÊÕ¼Ó·£¿î²»µ½Áùǧ¿é£¬Ô©ÁË£¿
ÒѾÓÐ0È˻ظ´
·´¸¯·ç±©Ï£¬ÖйúÒ©ÆóÈçºÎ×ßÉϺϹæÖ®Â·£¿
ÒѾÓÐ0È˻ظ´
Ô¤·ÀҽѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ103È˻ظ´
ѰÕÒ¸ÆîÑ¿óºÏ³É·½Ïò¿ÆÑÐÈËÔ±¡¢×¨¼Ò»òÑо¿ÉúºÏ×÷
ÒѾÓÐ0È˻ظ´
»·¾³¾ú¿ÉÄÜÔì³ÉµÄGMP·çÏÕ£¬¹úÄÚÏÖÔÚ¹Ø×¢µÄÆóÒµ¶àÂð£¿
ÒѾÓÐ0È˻ظ´
΢ÉúÎï»·¾³¾ú¿ÉÄÜÔì³ÉµÄGMP·çÏÕ
ÒѾÓÐ0È˻ظ´
Çó2020ÄêÒÔÀ´·ÅÉäҽѧ¼¼ÊõÊÓÆµ¡¢Ï°ÌâµÈ±¸¿¼×ÊÁÏ£¨×¨Òµ´úÂ룺206£©
ÒѾÓÐ0È˻ظ´
ÓжÔÊý×Ö΢Á÷¿Ø¼¼Êõ¸ÐÐËȤµÄÂ𣿻¶Ó½»Á÷
ÒѾÓÐ26È˻ظ´
ÉúÎïҽѧ¹¤³Ì270Çóµ÷¼Á£¬ÒÑÓÐһƪ¶þÇøÒ»×÷
ÒѾÓÐ16È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

943169490
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 20
- Ìû×Ó: 10
- ÔÚÏß: 8.4Сʱ
- ³æºÅ: 2361395
- ×¢²á: 2013-03-20
2Â¥2015-11-26 17:53:38
3Â¥2015-11-26 21:09:56
haioou
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 2 (Ó×¶ùÔ°)
- ½ð±Ò: 49.7
- É¢½ð: 22
- ºì»¨: 2
- Ìû×Ó: 157
- ÔÚÏß: 33.1Сʱ
- ³æºÅ: 3201097
- ×¢²á: 2014-05-12
- ÐÔ±ð: MM
- רҵ: ÁÙ´²Ò©Àí

4Â¥2015-11-27 19:11:49
ÐÂÊÖÒÑÉÏ·
ľ³æ (Ö°Òµ×÷¼Ò)
- Ó¦Öú: 82 (³õÖÐÉú)
- ½ð±Ò: 4153.3
- ºì»¨: 422
- Ìû×Ó: 4933
- ÔÚÏß: 616.2Сʱ
- ³æºÅ: 3474904
- ×¢²á: 2014-10-14
- ÐÔ±ð: GG
- רҵ: ÔªËØ»¯Ñ§

5Â¥2015-11-27 21:39:44
ÉîÇïÎíö°
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 5 (Ó×¶ùÔ°)
- ½ð±Ò: 2445
- É¢½ð: 39
- ºì»¨: 2
- Ìû×Ó: 308
- ÔÚÏß: 205.9Сʱ
- ³æºÅ: 1620824
- ×¢²á: 2012-02-16
- ÐÔ±ð: GG
- רҵ: Óлú·Ö×Ó¹¦ÄܲÄÁÏ»¯Ñ§
¡ï
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
Сľ³æ: ½ð±Ò+0.5, ¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÔÎÄÀ´ÁË |
» ±¾Ìû¸½¼þ×ÊÔ´Áбí
-
»¶Ó¼à¶½ºÍ·´À¡£ºÐ¡Ä¾³æ½öÌṩ½»Á÷ƽ̨£¬²»¶Ô¸ÃÄÚÈݸºÔð¡£
±¾ÄÚÈÝÓÉÓû§×ÔÖ÷·¢²¼£¬Èç¹ûÆäÄÚÈÝÉæ¼°µ½ÖªÊ¶²úȨÎÊÌ⣬ÆäÔðÈÎÔÚÓÚÓû§±¾ÈË£¬Èç¶Ô°æÈ¨ÓÐÒìÒ飬ÇëÁªÏµÓÊÏ䣺xiaomuchong@tal.com - ¸½¼þ 1 : VC¿¹°©Vitamin_C_selectively_kills_KRAS_and.pdf
2016-10-22 16:11:19, 1.74 M
6Â¥2016-10-22 16:12:06













»Ø¸´´ËÂ¥
haioou